Should You Buy Haemonetics Corporation Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Haemonetics Corporation (HAE) scores a robust 8.3/10 on our 32-signal Quality of Company framework. At the current market price of $106.20 and a $4.8B market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 3 of 11 CirclFi valuation models project upside for Haemonetics Corporation (HAE) at $106.20 — the model consensus leans bearish, with a Quality Score of 8.3/10 and Value-Trap risk of 31/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Haemonetics Corporation (HAE) in 2026?
What Is the Bull Case vs the Bear Case for Haemonetics Corporation (HAE)?
| Bull case — $165.46 target (+55.8%) | Bear case — $13.17 target (-87.6%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Haemonetics Corporation's quality score of 8.3/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation. | According to the CirclFi Deep Alpha Valuation Engine, the Earnings Power Value (EPV) model sees the stock as overvalued with a fair value of $13.17 (-87.6%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model targets a fair value of $165.46 (+55.8%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +143.4% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| Industry tailwind: licensing and M&A optionality could provide meaningful support for Haemonetics Corporation's revenue and margin trajectory in the Medical Devices space. | Industry headwind: generic/biosimilar competition represents a meaningful risk for Haemonetics Corporation and its Medical Devices peers. |
How Does HAE Compare to Its Medical Devices Peers?
Valuation data pages: ZBH · USAQ · XTNT · MDNC · CNMD · BVS · RCEL · CV · BJDX · IRMD · PODD
Which Other Stocks Score Like HAE on Quality?
Closest companies to HAE’s Quality of Company score of 8.3/10, across all industries.
- BMO — Bank of Montreal (QOC 8.3) · analysis
- WCC — WESCO International, Inc. (QOC 8.3) · analysis
- TXT — Textron Inc. (QOC 8.3) · analysis
- NUE — Nucor Corporation (QOC 8.3) · analysis
- AX — Axos Financial, Inc. (QOC 8.3) · analysis
- MGRC — McGrath RentCorp (QOC 8.3) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does HAE Appear In?
So Is Haemonetics Corporation (HAE) Worth Buying in 2026?
Caution dominates our read on Haemonetics Corporation at $106.20. 8 of 11 models see limited upside or outright downside, with the median fair value at $65.38 (-38.4%). Quality at 8.3/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.
These are quantitative model outputs, not investment recommendations. Haemonetics Corporation's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About HAE Stock?
Should I buy HAE stock right now?
Based on CirclFi's multi-model analysis, 3 of 11 models see upside for HAE at $106.20. The models are divided, which means the investment case depends heavily on your assumptions about Haemonetics Corporation's future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Haemonetics Corporation?
Key risks include: wide model disagreement (1156% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does HAE compare to its competitors?
Among Medical Devices peers, HAE holds a Quality Score of 8.3/10. Comparable companies include ZBH (QOC 8.4), USAQ (QOC 8.2), XTNT (QOC 8.4). The relative ranking helps investors identify whether HAE offers better fundamental quality than alternatives in the same sector.
Is HAE a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. HAE's Quality Score of 8.3/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy HAE at?
CirclFi does not provide target buy prices or price alerts. However, our 11 active models produce fair value estimates ranging from $13.17 to $165.46. At $106.20, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for HAE.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad